H.C. Wainwright Reiterates Buy Rating on Spring Works Therapeutics (SWTX)

August 29, 2024 8:16 AM EDT Send to a Friend
H.C. Wainwright analyst Robert Burns reiterated a Buy rating and $76.00 price target on Spring Works Therapeutics (NASDAQ: SWTX).The analyst ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login